Innate Pharma announces positive final results from the TELLOMAK Phase II study in Sézary syndrome, at the American Society of Hematology (ASH) 2023 annual meeting in San Diego, California.

The results confirm encouraging clinical activity, durable responses and a favorable safety profile for lacutamab in heavily pretreated patients who received mogamulizumab, according to the biopharmaceutical company.

Recruitment for the TELLOMAK study has been completed, and long-term follow-up will provide more mature data on the study's primary endpoints in due course", says Sonia Quaratino, Innate Pharma's Medical Director.

Copyright (c) 2023 CercleFinance.com. All rights reserved.